SEC Info - Target Corp - ‘10-K’ for 1/28/17

Target Corp – ‘10-K’ for 1/28/17 – ‘EX-10.CC’

On: Wednesday, 3/8/17, at 4:22pm ET · For: 1/28/17 · Accession #: 27419-17-8 · File #: 1-06049

Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 927K 2: EX-10.CC Material Contract HTML 48K 3: EX-10.I Material Contract HTML 285K 4: EX-10.S Material Contract HTML 68K 5: EX-10.U Material Contract HTML 69K 7: EX-21 Subsidiaries List HTML 36K 8: EX-23 Consent of Experts or Counsel HTML 39K 9: EX-24 Power of Attorney HTML 91K 6: EX-12 Statement re: Computation of Ratios HTML 48K 10: EX-31.A Certification -- §302 - SOA'02 HTML 43K 11: EX-31.B Certification -- §302 - SOA'02 HTML 43K 12: EX-32.A Certification -- §906 - SOA'02 HTML 38K 13: EX-32.B Certification -- §906 - SOA'02 HTML 38K 20: R1 Document and Entity Information HTML 65K 21: R2 Consolidated Statements of Operations HTML 113K 22: R3 Consolidated Statements of Comprehensive Income HTML 54K 23: R4 Consolidated Statements of Comprehensive Income HTML 43K (Parenthetical) 24: R5 Consolidated Statements of Financial Position HTML 134K 25: R6 Consolidated Statements of Financial Position HTML 58K (Parenthetical) 26: R7 Consolidated Statements of Cash Flows HTML 148K 27: R8 Consolidated Statements of Cash Flows HTML 40K (Parenthetical) 28: R9 Consolidated Statements of Shareholders' HTML 87K Investment 29: R10 Summary of Accounting Policies HTML 46K 30: R11 Revenues HTML 43K 31: R12 Cost of Sales and Selling, General and HTML 44K Administrative Expenses 32: R13 Consideration Received from Vendors HTML 40K 33: R14 Advertising Costs HTML 47K 34: R15 Pharmacies Transaction HTML 102K 35: R16 Canada Exit HTML 102K 36: R17 Restructuring Initiatives HTML 40K 37: R18 Credit Card Profit Sharing HTML 39K 38: R19 Fair Value Measurements HTML 79K 39: R20 Cash Equivalents HTML 42K 40: R21 Inventory HTML 42K 41: R22 Other Current Assets HTML 47K 42: R23 Property and Equipment HTML 55K 43: R24 Other Noncurrent Assets HTML 48K 44: R25 Goodwill and Intangible Assets HTML 74K 45: R26 Accounts Payable HTML 39K 46: R27 Accrued and Other Current Liabilities HTML 54K 47: R28 Commitments and Contingencies HTML 49K 48: R29 Notes Payable and Long-Term Debt HTML 77K 49: R30 Derivative Financial Instruments HTML 80K 50: R31 Leases HTML 83K 51: R32 Income Taxes HTML 111K 52: R33 Other Noncurrent Liabilities HTML 51K 53: R34 Share Repurchase HTML 46K 54: R35 Share-Based Compensation HTML 110K 55: R36 Defined Contribution Plans HTML 56K 56: R37 Pension and Postretirement Health Care Plans HTML 194K 57: R38 Accumulated Other Comprehensive Income HTML 61K 58: R39 Segment Reporting HTML 88K 59: R40 Quarterly Results (Unaudited) HTML 243K 60: R41 Summary of Accounting Policies (Policies) HTML 149K 61: R42 Advertising Costs (Tables) HTML 47K 62: R43 Pharmacies Transaction (Tables) HTML 71K 63: R44 Canada Exit (Tables) HTML 98K 64: R45 Fair Value Measurements (Tables) HTML 78K 65: R46 Other Current Assets (Tables) HTML 47K 66: R47 Property and Equipment (Tables) HTML 54K 67: R48 Other Noncurrent Assets (Tables) HTML 48K 68: R49 Goodwill and Intangible Assets (Tables) HTML 69K 69: R50 Accrued and Other Current Liabilities (Tables) HTML 54K 70: R51 Notes Payable and Long-Term Debt (Tables) HTML 79K 71: R52 Derivative Financial Instruments (Tables) HTML 76K 72: R53 Leases (Tables) HTML 76K 73: R54 Income Taxes (Tables) HTML 109K 74: R55 Other Noncurrent Liabilities (Tables) HTML 50K 75: R56 Share Repurchase (Tables) HTML 47K 76: R57 Share-Based Compensation (Tables) HTML 109K 77: R58 Defined Contribution Plans (Tables) HTML 52K 78: R59 Pension and Postretirement Health Care Plans HTML 199K (Tables) 79: R60 Accumulated Other Comprehensive Income (Tables) HTML 58K 80: R61 Segment Reporting (Tables) HTML 84K 81: R62 Quarterly Results (Unaudited) (Tables) HTML 244K 82: R63 Summary of Accounting Policies (Details) HTML 42K 83: R64 Revenues (Details) HTML 48K 84: R65 Advertising Costs (Details) HTML 43K 85: R66 Pharmacies Transaction - Narrative (Details) HTML 51K 86: R67 Pharmacies Transaction - Schedule of Gain on HTML 66K Pharmacies and Clinics Transaction (Details) 87: R68 Canada Exit - Narrative (Details) HTML 55K 88: R69 Canada Exit - Schedule of Income/(Loss) on HTML 75K Discontinued Operations (Details) 89: R70 Canada Exit - Schedule of Pretax Exit Costs HTML 48K (Details) 90: R71 Canada Exit - Schedule of Assets and Liabilities HTML 54K of Discontinued Operations (Details) 91: R72 Restructuring Initiatives - Narrative (Details) HTML 43K 92: R73 Credit Card Profit Sharing (Details) HTML 39K 93: R74 Fair Value Measurements - Schedule of Fair Value HTML 66K Measurements - Recurring Basis (Details) 94: R75 Fair Value Measurements - Schedule of Significant HTML 43K Financial Instruments not Measured at Fair Value (Details) 95: R76 Cash Equivalents (Details) HTML 44K 96: R77 Inventory (Details) HTML 39K 97: R78 Other Current Assets (Details) HTML 47K 98: R79 Property and Equipment (Details) HTML 62K 99: R80 Other Noncurrent Assets (Details) HTML 47K 100: R81 Goodwill and Intangible Assets - Narrative HTML 50K (Details) 101: R82 Goodwill and Intangible Assets - Schedule of HTML 65K Intangible Assets (Details) 102: R83 Goodwill and Intangible Assets - Schedule of HTML 48K Estimated Amortization Expense (Details) 103: R84 Accounts Payable (Details) HTML 40K 104: R85 Accrued and Other Current Liabilities (Details) HTML 63K 105: R86 Commitments and Contingencies - Narrative HTML 65K (Details) 106: R87 Notes Payable and Long-Term Debt - Narrative HTML 73K (Details) 107: R88 Notes Payable and Long-Term Debt - Schedule of HTML 66K Carrying Value and Maturities of Debt Portfolio (Details) 108: R89 Notes Payable and Long-Term Debt - Schedule of HTML 50K Required Principal Payments (Details) 109: R90 Notes Payable and Long-Term Debt - Schedule of HTML 47K Commercial Paper (Details) 110: R91 Derivative Financial Instruments - Narrative HTML 43K (Details) 111: R92 Derivative Financial Instruments - Schedule of HTML 53K Outstanding Interest Rate Swap Summary (Details) 112: R93 Derivative Financial Instruments - Schedule of HTML 55K Classification and Fair Value (Details) 113: R94 Derivative Financial Instruments - Schedule of HTML 41K Derivative Contracts - Effect on Results of Operations (Details) 114: R95 Leases - Narrative (Details) HTML 53K 115: R96 Leases - Schedule of Rent Expense (Details) HTML 43K 116: R97 Leases - Schedule of Future Minimum Lease Payments HTML 117K (Details) 117: R98 Income Taxes - Narrative (Details) HTML 66K 118: R99 Income Taxes - Schedule of Tax Rate Reconciliation HTML 58K - Continuing Operations (Details) 119: R100 Income Taxes - Schedule of Provision for Income HTML 72K Taxes (Details) 120: R101 Income Taxes - Schedule of Net Deferred Tax HTML 71K Asset/(Liability) (Details) 121: R102 Income Taxes - Schedule of Reconciliation of HTML 50K Liability for Unrecognized Tax Benefits (Details) 122: R103 Other Noncurrent Liabilities (Details) HTML 57K 123: R104 Share Repurchase - Schedule of Share Repurchases HTML 44K (Details) 124: R105 Share-Based Compensation - Narrative (Details) HTML 93K 125: R106 Share-Based Compensation - Schedule of Restricted HTML 73K Stock Activity and Performance Share Unit Activity (Details) 126: R107 Share-Based Compensation - Schedule of Stock HTML 71K Option Activity (Details) 127: R108 Share-Based Compensation - Schedule of Stock HTML 44K Option Exercises (Details) 128: R109 Defined Contribution Plans (Details) HTML 63K 129: R110 Pension and Postretirement Health Care Plans - HTML 52K Schedule of Recognition of Funded/(Underfunded) Status (Details) 130: R111 Pension and Postretirement Health Care Plans - HTML 52K Schedule of Estimated Future Benefit Payments (Details) 131: R112 Pension and Postretirement Health Care Plans - HTML 58K Schedule of Net Pension Benefit Expense (Details) 132: R113 Pension and Postretirement Health Care Plans - HTML 43K Schedule of Benefit Obligation Weighted Average Assumptions (Details) 133: R114 Pension and Postretirement Health Care Plans - HTML 46K Schedule of Net Periodic Benefit Expense Weighted Average Assumptions (Details) 134: R115 Pension and Postretirement Health Care Plans - HTML 78K Narrative (Details) 135: R116 Pension and Postretirement Health Care Plans - HTML 64K Schedule of Change in Projected Benefit Obligation (Details) 136: R117 Pension and Postretirement Health Care Plans - HTML 61K Schedule of Change in Plan Assets (Details) 137: R118 Pension and Postretirement Health Care Plans - HTML 61K Schedule of Asset Category (Details) 138: R119 Pension and Postretirement Health Care Plans - HTML 64K Schedule of Fair Value Measurements (Details) 139: R120 Pension and Postretirement Health Care Plans - HTML 57K Schedule of Amounts in Accumulated Other Comprehensive Income (Details) 140: R121 Accumulated Other Comprehensive Income (Details) HTML 74K 141: R122 Segment Reporting - Schedule of Business Segment HTML 79K Results (Details) 142: R123 Segment Reporting - Schedule of Total Assets by HTML 46K Segments (Details) 143: R124 Quarterly Results (Unaudited) - Schedule of HTML 115K Quarterly Results (Details) 144: R125 Quarterly Results (Unaudited) - Summary of Sales HTML 59K by Product Category (Details) 146: XML IDEA XML File -- Filing Summary XML 265K 145: EXCEL IDEA Workbook of Financial Reports XLSX 136K 14: EX-101.INS XBRL Instance -- tgt-20170128 XML 3.69M 16: EX-101.CAL XBRL Calculations -- tgt-20170128_cal XML 404K 17: EX-101.DEF XBRL Definitions -- tgt-20170128_def XML 842K 18: EX-101.LAB XBRL Labels -- tgt-20170128_lab XML 2.55M 19: EX-101.PRE XBRL Presentations -- tgt-20170128_pre XML 1.50M 15: EX-101.SCH XBRL Schema -- tgt-20170128 XSD 296K 147: ZIP XBRL Zipped Folder -- 0000027419-17-000008-xbrl Zip 345K

(a) Script Growth Performance Target. The Parties will measure the script volume of each of the Pharmacies existing [*] (the “Pre-Period Volume”). On [*], the Parties will measure the script volume of the Store Growth Group for the twelve month period preceding [*] (the “Post-Period Volume”). In the event the cumulative growth percentage of the [*] (the “Performance Target”), CVS shall pay to Target $[*] million for each [*] shortfall in the Performance Target, provided that such payment shall not exceed $[*] million in the aggregate. Any such payment shall be made to Target within seventy-five (75) days after the end of such [*] ([*]) year period. Beginning with [*], CVS agrees that it will plan for business growth at the Pharmacies in a manner that is [*]. In the event (i) the cumulative growth for the previous [*] period in total script volume on a [*] as of each January 1st (commencing after [*]) is less than [*]% of the [*] (based on IMS Health listings or a comparable source determined by the Parties in good faith) (the “Shortfall”), and (ii) the Shortfall is more than [*] ([*]) percentage points greater than the shortfall would be if only the [*] (as determined above), then CVS shall engage a nationally recognized consulting company (the “Consultant”), at its own cost and expense, to review the Shortfall and recommend how to decrease or eliminate the Shortfall. Target shall have the right to approve the Consultant, which approval shall not be unreasonably withheld, conditioned or delayed, and to receive a copy of the Consultant’s report. As long as the condition described in clause (ii) above continues, CVS shall implement the Consultant's recommendations in the order that CVS determines to be most effective to remediate the condition, provided that they do not require operational or other changes to the Stores (except with respect to the Pharmacies), and shall also dedicate a senior officer to oversee the Consultant’s work and the implementation of the Consultant’s recommendation(s) and to regularly update the Target Senior Officer on the progress of the implementation.

This ‘10-K’ Filing

Date

Other Filings

Filed on:

3/8/17

For Period end:

1/28/17

11/30/16

12/16/15

8-K

List all Filings

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/13/24 Target Corp. 10-K 2/03/24 131:11M 3/08/23 Target Corp. 10-K 1/28/23 127:12M 3/09/22 Target Corp. 10-K 1/29/22 124:11M 3/10/21 Target Corp. 10-K 1/30/21 130:12M 7/13/17 SEC UPLOAD¶ 9/21/17 1:35K Target Corp. 6/12/17 SEC UPLOAD¶ 9/21/17 1:41K Target Corp. 5/30/17 SEC UPLOAD¶ 9/21/17 1:136K Target Corp. 5/12/17 SEC UPLOAD¶ 9/21/17 1:137K Target Corp.



				TARGET CORPORATION

				/s/ *John Mulligan*
				John Mulligan
				Executive Vice President &
				Chief Operating Officer



				CVS PHARMACY, INC.

				/s/ *David M. Denton*
				David M. Denton
				Executive Vice President &
				Chief Financial Officer

Target Corp – ‘10-K’ for 1/28/17 – ‘EX-10.CC’

On: Wednesday, 3/8/17, at 4:22pm ET · For: 1/28/17 · Accession #: 27419-17-8 · File #: 1-06049

Previous ‘10-K’: ‘10-K’ on 3/11/16 for 1/30/16 · Next: ‘10-K’ on 3/14/18 for 2/3/18 · Latest: ‘10-K’ on 3/13/24 for 2/3/24 · 8 References:

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘EX-10.CC’ — Material Contract

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

8 Subsequent Filings that Reference this Filing

Target Corp – ‘10-K’ for 1/28/17 – ‘EX-10.CC’

On: Wednesday, 3/8/17, at 4:22pm ET · For: 1/28/17 · Accession #: 27419-17-8 · File #: 1-06049

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-10.CC’ — Material Contract

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

8 Subsequent Filings that Reference this Filing

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents